GlassScriptPhysician profile
Muhammad B Khan
NPI 1699200634
$2,429.46
in general payments reported to CMS, 2019-2025
22 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $189 · 2021: $384 · 2022: $410 · 2023: $700 · 2024: $567 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.78 |
| Education | $254.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $353.47 | 2021-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $347.66 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $292.20 | 2021-2024 | |
| Vifor Pharma, INC. | $260.24 | 2020-2023 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $258.12 | 2021-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $230.09 | 2020-2024 | Lokelma |
| Glaxosmithkline, LLC. | $145.21 | 2020-2022 | |
| Ardelyx, INC. | $99.74 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $93.12 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $49.84 | 2023-2024 | Ultomiris, Strensiq |
| Baxter Healthcare | $44.77 | 2024 | |
| Veloxis Pharmaceuticals, INC. | $35.09 | 2025 | |
| Boston Scientific Corporation | $29.51 | 2023 | Watchman Flx |
| Cormedix INC. | $26.84 | 2025 | Defencath |
| Neurocrine Biosciences, INC. | $24.87 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Amgen INC. | $23.60 | 2022 | |
| Abbvie INC. | $22.96 | 2024 | |
| Renalytix Ai, INC. | $21.86 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Fresenius USA Marketing, INC. | $20.07 | 2022 | |
| Smith+Nephew, INC. | $17.09 | 2025 | Collagenase Santyl |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.